world
Tesla fans told by Dutch safety regulator to stop pressuring agency on 'FSD Supervised'
Dutch automotive safety regulator RDW said that Tesla is working to gain approval to make its “FSD Supervised” systems available in the Netherlands. Source link
Anthropic unveils Claude Opus 4.5, its latest AI model following $350 billion valuation
Anthropic says its new Claude Opus 4.5 excels at coding, using computers and assisting users with complex enterprise tasks. Source link
Amazon to spend up to $50 billion on AI infrastructure for U.S. government
The project will add 1.3 gigawatts of capacity across new data centers, with Amazon expected to break ground in 2026. Source link
Trump appoints two Commerce officials to oversee U.S. Steel under 'golden share' agreement
President Donald Trump approved U.S. Steel’s controversial acquisition by Nippon in June after securing veto rights over key business decisions. Source link
Trump spoke with Chinese President Xi, White House says
President Donald Trump and Chinese leader Xi Jinping met last month in South Korea, where they reached some agreements on tariffs and other trade issues. Source link
Michael Burry launches newsletter to lay out his AI bubble views after deregistering hedge fund
“The Big Short” investor is capitalizing on the massive audience he’s built on X, where 1.6 million followers have long parsed his cryptic posts. Source link
Kohl's names Michael Bender as permanent CEO after a turbulent year and sales declines
Kohl’s has has multiple CEOs in recent years and is struggling with declining sales. Source link
Here's what's behind Tesla’s 3-year sales low in China
Tesla sales in China dropped to a three-year low in October and the electric vehicle maker could see its first full-year sales decline in the country this year. Source link
How Alibaba overcame Beijing's crackdown to become an AI giant
The Alibaba empire was once under intense scrutiny from Beijing and competition from rivals. Now a big AI bet is helping it stage a revival. Source link
Novo Nordisk shares plunge 9% after Alzheimer's drug trial fails to hit key target
Shares of Novo Nordisk plunged after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer’s disease failed to meet its main goal. Source link